Notice
Prof. Michelle L. Hastings - Antisense Oligonucleotides for the Treatment of Disease
- document 1 document 2 document 3
- niveau 1 niveau 2 niveau 3
Descriptif
Antisense oligonucleotides (ASOs) have proven to be an effective therapeutic platform for the treatment of disease. These short, single-stranded, modified nucleotides function by base-pairing with the complementary sequence of an RNA and modulating gene expression in a manner that is dependent on ASO design and targeting site. We have devised a number of approaches to alter splicing with ASOs to correct or improve gene expression and pathology in disease models. One of our approaches is under development for the treatment of CLN3 Batten disease, a fatal, pediatric lysosomal storage disease caused by mutations in a gene encoding the lysosomal membrane protein CLN3. The most common mutation associated with CLN3 Batten is a deletion of exons 7 and 8 (CLN3Δex78), which disrupts the mRNA open reading frame. We devised a therapeutic strategy for treating CLN3 Batten disease using an ASO that alters splicing CLN3 splicing to correct the open reading frame of the mutated transcript. Treatment of CLN3Δex78 neonatal mice with this ASO resulted in the desired splicing effect throughout the central nervous system, improved motor coordination, reduced histopathological features of the disease in the brain and extended life in a severe mouse model of the disease. Our results demonstrate that ASO-mediated reading frame correction is a promising therapeutic approach for CLN3 Batten disease.
Thème
Dans la même collection
-
Dr Lori L. Isom - Dancing to a different tune: TANGO offers a precision medicine approach to treati…
Dravet syndrome is an intractable developmental and epileptic encephalopathy caused largely by de novo variants in SCN1A resulting in haploinsufficiency of the voltage-gated sodium channel α subunit
-
Dr Ana Cristina Calvo - Peripheral RNA Biomarkers in Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of unknown origin that causes progressive muscle paralysis and motor neuron death.
-
Prof. Antonella Riccio - RNA metabolism in developing neurons
Neurons are cells with a complex morphology, which maintain their cellular structure through the compartmentalized expression of proteins essential for growth and plasticity.
-
Dr Débora Lanznaster - Combined Metabolomics and targeted-transcriptomics analysis in the muscle of…
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the progressive loss of motor neurons, leading to paralysis and death of patients after 3-5 years of symptoms’ onset
-
Director Jason Potter - What matters for making highly expressed mRNA.
The need for high quality mRNA for therapeutic applications has grown substantially over the last few years due to the efficacy of the COVID mRNA vaccines.
-
Dr Horacio Cabral - RNA/Polymer-Based Supramolecular Approaches for mRNA Delivery
Messenger RNA (mRNA) therapeutics are attracting much attention, particularly after the approval of two mRNA vaccine formulations for COVID-19.
-
Prof. Krzystof Sobczak - Compounds which alleviate the pleiotropic toxicity of RNA harboring expand…
Fragile X-associated tremor/ataxia syndrome (FXTAS) is an incurable neurodegenerative disorder caused by expansion of CGG repeats in the FMR1 5'UTR.
-
Prof. Steven Dowdy - Delivery of RNA Therapeutics: The Great Endosomal Escape!
All macromolecular therapeutics, including ASOs, siRNAs, peptides, proteins, CRISPR, mRNA and non-viral DNA vectors, are taken up into cells by endocytosis.
-
Dr Liliane Massade - Squalenoyl siRNA PMP22 nanoparticles, a potent therapy for Charcot-Marie-Tooth…
Charcot-Marie-Tooth disease type 1A (CMT1A), caused by a duplication in chromosome 17, results in peripheral myelin protein 22 (Pmp22) over-expression and axon demyelination.
-
Prof. Jernej Ule - How do protein-RNA condensates form and contribute to disease?
Mutations in many genes encoding RNA-binding proteins (RBPs) cause neurologic diseases, and especially the amyotrophic lateral sclerosis (ALS).
-
Prof. Stefano Gustincich - Antisense long non-coding SINEUP RNAs: from molecular mechanism to thera…
Natural SINEUPs are antisense long non-coding RNAs that enhance translation of sense mRNAs. Their activity depends on the combination of two domains: the overlapping region, or binding domain (BD),
